JP2020505448A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505448A5 JP2020505448A5 JP2019559015A JP2019559015A JP2020505448A5 JP 2020505448 A5 JP2020505448 A5 JP 2020505448A5 JP 2019559015 A JP2019559015 A JP 2019559015A JP 2019559015 A JP2019559015 A JP 2019559015A JP 2020505448 A5 JP2020505448 A5 JP 2020505448A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- composition according
- effective amount
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 51
- 150000001875 compounds Chemical class 0.000 claims description 26
- 239000000651 prodrug Substances 0.000 claims description 18
- 229940002612 prodrug Drugs 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 208000023105 Huntington disease Diseases 0.000 claims description 16
- 102000011690 Adiponectin Human genes 0.000 claims description 13
- 108010076365 Adiponectin Proteins 0.000 claims description 13
- 210000000577 adipose tissue Anatomy 0.000 claims description 8
- 230000004153 glucose metabolism Effects 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 210000001789 adipocyte Anatomy 0.000 claims description 4
- 230000036528 appetite Effects 0.000 claims description 4
- 235000019789 appetite Nutrition 0.000 claims description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 4
- 210000004958 brain cell Anatomy 0.000 claims description 4
- 230000001934 delay Effects 0.000 claims description 4
- 230000010120 metabolic dysregulation Effects 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 230000003442 weekly effect Effects 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 230000003203 everyday effect Effects 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447741P | 2017-01-18 | 2017-01-18 | |
| US62/447,741 | 2017-01-18 | ||
| PCT/US2018/014240 WO2018136635A1 (en) | 2017-01-18 | 2018-01-18 | Pparϒ agonist for the treatment of huntington's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505448A JP2020505448A (ja) | 2020-02-20 |
| JP2020505448A5 true JP2020505448A5 (cg-RX-API-DMAC7.html) | 2021-02-25 |
Family
ID=62908392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559015A Pending JP2020505448A (ja) | 2017-01-18 | 2018-01-18 | ハンチントン病の治療のためのＰＰＡＲγアゴニスト |
Country Status (13)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220070057A (ko) | 2015-03-09 | 2022-05-27 | 인테크린 테라퓨틱스, 아이엔씨. | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
| SG11201909046XA (en) | 2017-04-03 | 2019-10-30 | Coherus Biosciences Inc | PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895541B2 (en) * | 2002-09-04 | 2014-11-25 | James A. Carnazza | Methods for inhibiting the development of huntington's disease |
| US20040224995A1 (en) * | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| DE10351744A1 (de) * | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| CA2583606A1 (en) * | 2004-10-13 | 2006-04-27 | University Of Connecticut | Cannabinergic lipid ligands |
| WO2009097996A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms |
| WO2010040055A2 (en) * | 2008-10-03 | 2010-04-08 | Intekrin Therapeutics, Inc. | Oral pharmaceutical formulations for antidiabetic compounds |
| US9028879B2 (en) * | 2009-07-01 | 2015-05-12 | Jds Therapeutics, Llc | Chromium complexes as enhancers of brain glucose transporters |
| MX2016008027A (es) * | 2013-12-20 | 2016-10-12 | Teva Pharma | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. |
-
2018
- 2018-01-18 CN CN201880007571.4A patent/CN110461330A/zh active Pending
- 2018-01-18 BR BR112019014529-0A patent/BR112019014529A2/pt not_active Application Discontinuation
- 2018-01-18 JP JP2019559015A patent/JP2020505448A/ja active Pending
- 2018-01-18 EP EP18741523.7A patent/EP3570841A4/en not_active Withdrawn
- 2018-01-18 CA CA3050104A patent/CA3050104A1/en not_active Abandoned
- 2018-01-18 EA EA201991716A patent/EA201991716A1/ru unknown
- 2018-01-18 MX MX2019008535A patent/MX2019008535A/es unknown
- 2018-01-18 AU AU2018210165A patent/AU2018210165A1/en not_active Abandoned
- 2018-01-18 SG SG11201906644YA patent/SG11201906644YA/en unknown
- 2018-01-18 US US16/476,979 patent/US20190350918A1/en not_active Abandoned
- 2018-01-18 WO PCT/US2018/014240 patent/WO2018136635A1/en not_active Ceased
- 2018-01-18 KR KR1020197023202A patent/KR20190122664A/ko not_active Ceased
-
2019
- 2019-07-11 IL IL268008A patent/IL268008A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3043785B1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| ES2577930T3 (es) | Derivados de triazina para retrasar el inicio de la diabetes tipo 1 | |
| JP7265990B2 (ja) | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 | |
| JP2020536905A5 (cg-RX-API-DMAC7.html) | ||
| JP2013545730A5 (cg-RX-API-DMAC7.html) | ||
| JP2016193932A5 (cg-RX-API-DMAC7.html) | ||
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EP3226873B1 (en) | Compositions comprising 15-hepe and its use for treating or preventing idiopathic pulomonary fibrosis | |
| PE20160195A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| EA200800056A1 (ru) | Каннабиноидный активный фармацевтический ингредиент для лекарственных форм | |
| RU2010143864A (ru) | Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов | |
| JP2018538306A5 (cg-RX-API-DMAC7.html) | ||
| JP2020505448A5 (cg-RX-API-DMAC7.html) | ||
| IL292770A (en) | Formulations and doses of pegylated uricase | |
| JP2019531356A5 (cg-RX-API-DMAC7.html) | ||
| RU2005131845A (ru) | Способ лечения легкого ухудшения познавательной способности и предотвращения или задержки начала болезни альцгеймера | |
| RU2012150501A (ru) | Противораковые стероидные лактоны, ненасыщенные в положении 7(8) | |
| BR112012022052A2 (pt) | método para o tratamento ou prevenção de sintomas da variação hormonal, composição farmacêutica para o tratamento ou prevenção de sintomas da variação hormonal e kit para o tratamento ou prevenção de sintomas da variação hormonal | |
| JP2018502163A5 (cg-RX-API-DMAC7.html) | ||
| JP2019507786A5 (cg-RX-API-DMAC7.html) | ||
| JP2019524888A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| JP2019515033A5 (cg-RX-API-DMAC7.html) | ||
| RU2013157834A (ru) | Композиции для подкожного введения физиологически активных средств | |
| JP2019524889A5 (cg-RX-API-DMAC7.html) |